drugset / Trial / NCT03630029
RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD
Non-randomizedSequentialOpen-labelPrevention
Summary
A Phase 1b study to evaluate the safety, tolerability and pharmacodynamic effect of RBT-1 in healthy volunteers and subjects with stage 3b-4 CKD.
Timeline
- Start
- 2018-09-15
- Primary completion
- 2018-11-30
- Completion
- 2019-03-31
Outcome
Outcome not reported
Stopped: “The trial has been enhanced, a new NCT(NCT03893799) listing was created.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iron sucrose | Unknown | 12 mg | — |
| Subject | Iron sucrose | Unknown | 60 mg | — |
| Subject | Iron sucrose | Unknown | 120 mg | — |
| Subject | Iron sucrose | Unknown | 180 mg | — |
| Subject | RBT-9 | Small molecule | 9 mg | — |
| Subject | RBT-9 | Small molecule | 45 mg | — |
| Subject | RBT-9 | Small molecule | 90 mg | — |
| Subject | RBT-9 | Small molecule | 135 mg | — |